Search

Your search keyword '"Uchida, Yoshihito"' showing total 214 results

Search Constraints

Start Over You searched for: Author "Uchida, Yoshihito" Remove constraint Author: "Uchida, Yoshihito"
214 results on '"Uchida, Yoshihito"'

Search Results

2. Evaluation of an immunochromatography-based rapid antigen test, Inspecter Kowa® SARS-CoV-2, using saliva specimens for the detection of SARS-CoV-2

3. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.

4. Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial: Effect of ipragliflozin in MASLD

5. Nationwide survey for patients with acute-on-chronic liver failure occurring between 2017 and 2019 and diagnosed according to proposed Japanese criteria

6. 拠点病院以外の肝疾患専門医療機関における院内肝炎ウイルス陽性者対策調査

8. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.

9. 肝疾患診療連携拠点病院における肝炎医療コーディネーターの現状(第2報)

10. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

12. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

13. Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir

14. Portal venous blood flows determine liver function in patients with decompensated cirrhosis due to HCV infection receiving successful sofosbuvir/velpatasvir therapy

16. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals

19. Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies

23. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study

24. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog

25. Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation

33. Present status of hepatitis medical care coordinators in regional core centers in Japan

36. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis

37. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis

38. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

40. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus

41. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate

42. Abstracts of selected papers presented at the 79th general meeting of the Japanese Society of Gastroenterology March 29–31, 1993, Kyoto, Japan

45. A case of genotype‐3b hepatitis C virus in which the whole genome was successfully analyzed using third‐generation nanopore sequencing

46. Deteriorated outcome of recent patients with acute liver failure and late‐onset hepatic failure caused by infection with hepatitis A virus: A subanalysis of patients seen between 1998 and 2015 and enrolled in nationwide surveys in Japan

49. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy

Catalog

Books, media, physical & digital resources